This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kyrle, P. A. Articles by Lechner, K. Search for Related Content PubMed PubMed Citation Articles by Kyrle, P. A. Articles by Lechner, K. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB ACETYLSALICYLIC ACID

Circulation, Vol 75, 1025-1029, Copyright © 1987 by American Heart Association

ARTICLES

Inhibition of prostacyclin and thromboxane A2 generation by low-dose aspirin at the site of plug formation in man in vivo

PA Kyrle, HG Eichler, U Jager and K Lechner

In a double-blind placebo-controlled crossover study, we investigated in seven healthy male volunteers the effect of a low-dose aspirin regimen (35 mg acetylsalicylate per day for 7 days) on the formation of thromboxane A2 (TxA2) and prostacyclin (PGI2) in blood emerging from a standardized injury of the microvasculature made to determine skin bleeding time. When subjects were treated with placebo, there was rapid and substantial generation of TxA2 and PGI2 at the site of platelet- vessel wall interaction within the first 2 min after vascular injury. This was reflected by a greater than 100-fold and greater than 10-fold increase in thromboxane B2 (TxB2) and 6-keto-prostaglandin F1 alpha (6- keto-PGF1 alpha) in blood obtained from incisions made to determine bleeding time as compared with the corresponding plasma values. Low- dose aspirin caused a significant inhibition of both TxA2 and PGI2 generation in blood sampled from the skin incisions, represented by a 85% and 92% and 81% and 84% inhibition of TxB2 and 6-keto-PGF1 alpha, respectively, as compared with controls. We therefore conclude that rapid activation of both platelet prostaglandin metabolism and vascular PGI2 biosynthesis occurs at the site of platelet-vessel wall interaction, and low-dose aspirin results in a significant inhibition of both platelet and vascular cyclooxygenase activity. Thus, our data fail to confirm the concept of a differential effect of low-dose aspirin on platelet and vascular prostaglandin synthesis in man in vivo.

This article has been cited by other articles:

				L. A. Holowatz, J. D. Jennings, J. A. Lang, and W. L. Kenney Ketorolac alters blood flow during normothermia but not during hyperthermia in middle-aged human skin J Appl Physiol, October 1, 2009; 107(4): 1121 - 1127. [Abstract] [Full Text] [PDF]

				L. A. Holowatz and W. L. Kenney Chronic low-dose aspirin therapy attenuates reflex cutaneous vasodilation in middle-aged humans J Appl Physiol, February 1, 2009; 106(2): 500 - 505. [Abstract] [Full Text] [PDF]

				J. A. Mitchell, R. Lucas, I. Vojnovic, K. Hasan, J. R. Pepper, and T. D. Warner Stronger inhibition by nonsteroid anti-inflammatory drugs of cyclooxygenase-1 in endothelial cells than platelets offers an explanation for increased risk of thrombotic events FASEB J, December 1, 2006; 20(14): 2468 - 2475. [Abstract] [Full Text] [PDF]

				E. Tuleja, F. Mejza, A. Cmiel, and A. Szczeklik Effects of Cyclooxygenases Inhibitors on Vasoactive Prostanoids and Thrombin Generation at the Site of Microvascular Injury in Healthy Men Arterioscler Thromb Vasc Biol, June 1, 2003; 23(6): 1111 - 1115. [Abstract] [Full Text] [PDF]

				C. A.J. Farquharson, R. Butler, A. Hill, J. J.F. Belch, and A. D. Struthers Allopurinol Improves Endothelial Dysfunction in Chronic Heart Failure Circulation, July 9, 2002; 106(2): 221 - 226. [Abstract] [Full Text] [PDF]

				C. A. J. Farquharson and A. D. Struthers Spironolactone Increases Nitric Oxide Bioactivity, Improves Endothelial Vasodilator Dysfunction, and Suppresses Vascular Angiotensin I/Angiotensin II Conversion in Patients With Chronic Heart Failure Circulation, February 15, 2000; 101(6): 594 - 597. [Abstract] [Full Text] [PDF]

				R. Altman Controversies in Antithrombotic Therapy in Cardiovascular Diseases Clinical and Applied Thrombosis/Hemostasis, January 1, 1998; 4(1): 11 - 24. [Abstract] [PDF]

				M. J. Eisenberg and E. J. Topol Prehospital Administration of Aspirin in Patients With Unstable Angina and Acute Myocardial Infarction Arch Intern Med, July 22, 1996; 156(14): 1506 - 1510. [Abstract] [PDF]

				S. Eichinger, M. Wolzt, B. Schneider, M. Nieszpaur-Los, H. Heinrichs, K. Lechner, H.-G. Eichler, and P. A. Kyrle Effects of Recombinant Hirudin (r-Hirudin, HBW 023) on Coagulation and Platelet Activation In Vivo : Comparison With Unfractionated Heparin and a Low-Molecular-Weight Heparin Preparation (Fragmin) Arterioscler Thromb Vasc Biol, July 1, 1995; 15(7): 886 - 892. [Abstract] [Full Text]

				E. Minar, A. Ahmadi, R. Koppensteiner, Th. Maca, A. Stumpflen, A. Ugurluoglu, and H. Ehringer Comparison of Effects of High-Dose and Low-Dose Aspirin on Restenosis After Femoropopliteal Percutaneous Transluminal Angioplasty Circulation, April 15, 1995; 91(8): 2167 - 2173. [Abstract] [Full Text]